Class of chemical compounds
Substituted piperazines are a class ofchemical compounds based on apiperazine core.[ 1] recreational drugs and some are used inscientific research .[ 2]
List of substituted piperazines [ edit ] Chemical structures of selected benzylpiperazines
Befuraline (also produces benzylpiperazine as a metabolite)
Fipexide (also produces substituted benzylpiperazine as a metabolite)
Piberaline (also produces benzylpiperazine as a metabolite)
Enpiprazole is known to produce oCPP as a metabolite. It was initially anticipated to produce oMeOPP as a metabolite, but this proved not to be the case.
Trazodone ,nefazodone ,etoperidone ,mepiprazole , and others produce mCPP as a metabolite.[ 3]
Multiple substitutions [ edit ] Other arylpiperazines [ edit ] Manyazapirones such asbuspirone ,gepirone , andtandospirone produce 1-PP as ametabolite .
Monoamine release (EC50 Tooltip half-maximal effective concentration , nM) of arylpiperazines Compound PAL # Serotonin Norepinephrine Dopamine Type Ref 1-Benzylpiperazine (BZP)ND 6050–>100000 62.2–68 175–600 NDRA [ 5] [ 6] [ 7] [ 8] [ 9] [ 10] 1-Phenylpiperazine (PP)ND 880 186 2530 SNRA [ 11] 2-Me-PP (oMPP)PAL-169 175 39.1 296–542 SNDRA [ 11] [ 12] [ 10] 2-OMe-PP (oMeOPP)ND ND ND ND ND ND 2-TFM-PP (oTFMPP)ND 570 350 11200 SNRA [ 11] 2-SMe-PP (oMTPP)ND 270 >10000 >10000 SRA [ 11] 2-Et-PP (oEtPP)ND 290 830 >10000 SNRA [ 11] 2-Chloro-PP (oCPP)ND 310 26 >3000 NRA [ 11] 2-Bromo-PP (oBPP)ND 132 33 250 SNDRA [ 11] 2-Nitro-PP (oNPP)ND 1870 770 >10000 SNRA [ 11] 3-Chloro-PP (mCPP)ND 28–39 1400–>10000 >10000–63000 SRA [ 6] [ 13] [ 14] [ 15] 3-Fluoro-PP (mFPP)ND 115 340 2400 SNRA [ 11] 3-Me-PP (mMPP)ND 110 >20000 >20000 SRA [ 11] 3-OMe-PP (mMeOPP)ND 650 >10000 >10000 SRA [ 11] 3-OH-PP (mOHPP)ND 230 174 2500 SNRA [ 11] 3-TFM-PP (TFMPP)ND 121 >10000 >10000 SRA [ 8] [ 7] [ 9] 4-Chloro-PP (pCPP)ND ND ND ND ND ND 4-Fluoro-PP (pFPP)ND 230 3200 >10000 SRA [ 11] 4-Me-PP (pMPP)PAL-233 220 >10000 >20000 SRA [ 11] [ 10] 4-OMe-PP (pMeOPP)ND 3200 440–1500 6300–11000 SNDRA [ 11] [ 6] 4-TFM-PP (pTFMPP)ND ND ND ND ND ND 4-Ac-PP (pAcPP)ND 50 150 3000 SNRA [ 11] 4-CN-PP (pCNPP)ND 36 6300 >10000 SRA [ 11] 4-Phenyl-PP (pPhPP)ND >10000 1520 5200 NDRA [ 11] 4-OH-PP (pOHPP)ND >10000 230 850 NDRA [ 11] 4-Nitro-PP (pNPP)PAL-175 19–43 >10000 >10000 SRA [ 11] [ 4] 2,3-Dichloro-PP (2,3-DCPP)ND 10 36 108 SNDRA [ 11] 2,3-DiMe-PP (2,3-DMPP)PAL-218 24–26 13.7–56 1207–1320 SNRA [ 11] [ 4] [ 10] 2,4-Difluoro-PP (2,4-DFPP)ND 470 2300 >10000 SNRA [ 11] 3,4-Dichloro-PP (3,4-DCPP)ND ND ND ND ND ND 3,4-Difluoro-PP (3,4-DFPP)ND 76 9200 >10000 SRA [ 11] 3-TFM-4-Cl-PP (TFMCPP)PAL-179 33 >10000 >10000 SRA [ 4] Notes: Assays were done using rat brainsynaptosomes .
^ Laras, Y.; Garino, C.; Dessolin, J.; Weck, C.; Moret, V.; Rolland, A.; Kraus, J.-L. (2009-02-01)."New N4-substituted piperazine naphthamide derivatives as BACE-1 inhibitors" Journal of Enzyme Inhibition and Medicinal Chemistry .24 (1):181– 187.doi :10.1080/14756360802048939 .ISSN 1475-6366 .PMID 18770069 .S2CID 85385527 . ^ Alghamdi, Saad; Alshehri, Mohammed M.; Asif, Mohammad (2022)."The Neuropharmacological Potential of Piperazine Derivatives: A Mini- Review" Mini-Reviews in Organic Chemistry .19 (7):798– 810.doi :10.2174/1570193x19666220119120211 . ^ Costa Alegre MD, Barbosa DJ, Dinis-Oliveira RJ (February 2025). "Metabolism of m-CPP, trazodone, nefazodone, and etoperidone: clinical and forensic aspects".Drug Metab Rev .57 (2):115– 146.doi :10.1080/03602532.2025.2465482 .PMID 39945551 . ^a b c d e Rothman RB, Partilla JS, Baumann MH, Lightfoot-Siordia C, Blough BE (April 2012)."Studies of the biogenic amine transporters. 14. Identification of low-efficacy "partial" substrates for the biogenic amine transporters" .J Pharmacol Exp Ther .341 (1):251– 262.doi :10.1124/jpet.111.188946 .PMC 3364510 PMID 22271821 . ^ Rothman RB, Baumann MH (2006). "Therapeutic potential of monoamine transporter substrates".Curr Top Med Chem .6 (17):1845– 1859.doi :10.2174/156802606778249766 .PMID 17017961 . ^a b c Nagai F, Nonaka R, Satoh Hisashi Kamimura K (March 2007)."The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain" Eur J Pharmacol .559 (2– 3):132– 137.doi :10.1016/j.ejphar.2006.11.075 .PMID 17223101 . ^a b Baumann MH, Clark RD, Budzynski AG, Partilla JS, Blough BE, Rothman RB (October 2004). "Effects of "Legal X" piperazine analogs on dopamine and serotonin release in rat brain".Ann N Y Acad Sci .1025 :189– 197.Bibcode :2004NYASA1025..189B .doi :10.1196/annals.1316.024 .PMID 15542717 . ^a b Baumann MH, Clark RD, Budzynski AG, Partilla JS, Blough BE, Rothman RB (March 2005). "N-substituted piperazines abused by humans mimic the molecular mechanism of 3,4-methylenedioxymethamphetamine (MDMA, or 'Ecstasy')".Neuropsychopharmacology .30 (3):550– 560.doi :10.1038/sj.npp.1300585 .PMID 15496938 . ^a b Blough B (July 2008)."Dopamine-releasing agents" (PDF) . In Trudell ML, Izenwasser S (eds.).Dopamine Transporters: Chemistry, Biology and Pharmacology 305– 320.ISBN 978-0-470-11790-3 OCLC 181862653 .OL 18589888W . ^a b c d Reith ME, Blough BE, Hong WC, Jones KT, Schmitt KC, Baumann MH, Partilla JS, Rothman RB, Katz JL (February 2015)."Behavioral, biological, and chemical perspectives on atypical agents targeting the dopamine transporter" .Drug Alcohol Depend .147 :1– 19.doi :10.1016/j.drugalcdep.2014.12.005 .PMC 4297708 PMID 25548026 . ^a b c d e f g h i j k l m n o p q r s t u v w x Severinsen K, Kraft JF, Koldsø H, Vinberg KA, Rothman RB, Partilla JS, Wiborg O, Blough B, Schiøtt B, Sinning S (September 2012)."Binding of the amphetamine-like 1-phenyl-piperazine to monoamine transporters" .ACS Chem Neurosci .3 (9):693– 705.doi :10.1021/cn300040f .PMC 3447394 PMID 23019496 . ^ Kohut SJ, Jacobs DS, Rothman RB, Partilla JS, Bergman J, Blough BE (December 2017)."Cocaine-like discriminative stimulus effects of "norepinephrine-preferring" monoamine releasers: time course and interaction studies in rhesus monkeys" .Psychopharmacology (Berl) .234 (23– 24):3455– 3465.doi :10.1007/s00213-017-4731-5 .PMC 5747253 PMID 28889212 . ^ Rothman RB, Baumann MH (July 2002). "Therapeutic and adverse actions of serotonin transporter substrates".Pharmacol Ther .95 (1):73– 88.doi :10.1016/s0163-7258(02)00234-6 .PMID 12163129 . ^ Rothman RB, Baumann MH (April 2002). "Serotonin releasing agents. Neurochemical, therapeutic and adverse effects".Pharmacol Biochem Behav .71 (4):825– 836.doi :10.1016/s0091-3057(01)00669-4 .PMID 11888573 . ^ Rothman RB, Baumann MH, Blough BE, Jacobson AE, Rice KC, Partilla JS (November 2010)."Evidence for noncompetitive modulation of substrate-induced serotonin release" .Synapse .64 (11):862– 869.doi :10.1002/syn.20804 .PMC 2941209 PMID 20842720 .
Phenylpiperazines 1-Phenylpiperazine (1-PP; PP) 3,4-CFP 2C-B-PP Acaprazine Antrafenine Aripiprazole Batoprazine Bifeprunox BRL-15,572 Ciprofloxacin Dapiprazole DCPP DMPP Diphenylpiperazine Dropropizine EGIS-7625 EGIS-12,233 Elopiprazole Eltoprazine Enpiprazole Ensaculin Etoperidone Flesinoxan Fluanisone Flibanserin Fluprazine Itraconazole Ketoconazole Levodropropizine Lorpiprazole mCPP Mefway MeOPP Mepiprazole Naftopidil Naluzotan Nefazodone Niaprazine Oxypertine Pardoprunox pCPP pFPP Posaconazole S-14,506 S-14,671 S-15,535 SB-258,585 SB-271,046 SB-357,134 SB-399,885 Sonepiprazole TFMPP Tolpiprazole Trazodone Urapidil Vesnarinone Vilazodone Vortioxetine WAY-100,135 WAY-100,635 Benzylpiperazines Naphthylpiperazines Quinolinylpiperazines Diphenylalkylpiperazines Pyrimidinylpiperazines Pyridinylpiperazines Benzo(iso)thiazolyl piperazines Tricyclic -linked piperazinesOthers/uncategorized
